Listed

Kiora Pharmaceuticals Inc: Form 10-Q for the period ended Jun 30, 2017

Filed with the SEC on Aug 4, 2017 and accepted by EDGAR at Aug 4, 2017, 16:13 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2017-04-01 to 2017-06-30$2.3mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2017-01-01 to 2017-06-30$4.1mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2017-04-01 to 2017-06-30−$3.3mus-gaap:OperatingIncomeLoss
Operating income6 months2017-01-01 to 2017-06-30−$6.2mus-gaap:OperatingIncomeLoss
Interest expense3 months2017-04-01 to 2017-06-30$305us-gaap:InterestExpense
Interest expense6 months2017-01-01 to 2017-06-30$608us-gaap:InterestExpense
Diluted EPS3 months2017-04-01 to 2017-06-30−$0.28us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2017-01-01 to 2017-06-30−$0.55us-gaap:EarningsPerShareBasicAndDiluted
Cash and equivalentsAt period end2017-06-30$11.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2017-06-30$12.4mus-gaap:AssetsCurrent
Total assetsAt period end2017-06-30$18.3mus-gaap:Assets
Current liabilitiesAt period end2017-06-30$11.0mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2017-06-30$13.7mus-gaap:Liabilities
Shareholders' equityAt period end2017-06-30$4.6mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001144204-17-040582. Last ingested by Listed: Nov 12, 2026, 17:43 ET. Listed shows no prices and gives no investment advice.